TY - JOUR T1 - Clinical manifestations of patients with Coronavirus Disease 2019 (COVID-19) attending at hospitals in Bangladesh JF - medRxiv DO - 10.1101/2020.07.30.20165100 SP - 2020.07.30.20165100 AU - Md. Shahed Morshed AU - Abdullah Al Mosabbir AU - Prodipta Chowdhury AU - Sheikh Mohammad Ashadullah AU - Mohammad Sorowar Hossain Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/01/2020.07.30.20165100.abstract N2 - Bangladesh is in the rising phase of the ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, the scientific literature on clinical manifestations of COVID-19 patients from Bangladesh is virtually absent. This is the first study aimed to report the sociodemographic and clinical characteristics of patients with COVID-19 in Bangladesh. We conducted a cross-sectional study at three dedicated COVID-19 hospitals. A total of 103 RT-PCR confirmed non-critical COVID-19 patients were enrolled. Sociodemographic factors, underlying disease conditions, clinical symptoms and vital signs including oxygen saturation were documented and analyzed. The median age of the patients was 37 years (IQR: 31-53); most of the patients (71.8%) were male. Mild, moderate and severe illness were present in 74.76%, 9.71% and 15.53% of patients respectively. More than half (52.4%) patients had a co-morbidity, with hypertension being the most common (34%), followed by diabetes (21.4%) and Ischemic heart disease (9.7%). Fever (78.6%), weakness (68%) and cough (44.7%) were the most common clinical manifestations. Other common symptoms included loss of appetite (37.9%), difficulty breathing (37.9%), altered sensation of taste or smell (35.0%), headache (32%) and bodyache (32%). The median time from onset of symptom to attending hospitals was 7 days (IQR 4-10). This study will help both the clinicians and epidemiologists to understand the magnitude and clinical spectrum of COVID-19 patients in Bangladesh.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was associated with this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of Biomedical Research Foundation, Bangladesh approved the study protocol (Ref. no: BRF/ERB/2020/003).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable ER -